Anand Rathi's research report on Rossari Biotech
With a diversified product portfolio and a strong balance sheet, we believe Rossari Biotech is well positioned to capitalise on emerging opportunities and drive healthy growth in coming years. We expect it is likely to deliver 18%/22%/25% revenue/EBITDA/PAT CAGRs over FY25-27 due to swelling demand, capacity expansion and mounting exports.
Outlook
We expect a consistently better performance aided by capacity expansion, product launches and better margins. We value the stock at 25x FY27e EPS at a TP of Rs1,085.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
